---
document_datetime: 2024-06-24 16:16:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ocrevus-epar-all-authorised-presentations_en.pdf
document_name: ocrevus-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9138565
conversion_datetime: 2025-12-30 21:40:18.325157
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/17/1231/001 | Ocrevus           | 300 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (30 mg/ml)          | 1 vial      |
| EU/1/17/1231/002 | Ocrevus           | 300 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 10 ml (30 mg/ml)          | 2 vials     |
| EU/1/17/1231/003 | Ocrevus           | 920 mg     | Solution for injection                | Subcutaneous use          | vial (glass)          | 23 ml (40 mg/ml)          | 1 vial      |